Pamelor is a brand name of nortriptyline, approved by the FDA in the following formulation(s):
PAMELOR (nortriptyline hydrochloride - capsule; oral)
Manufacturer: MALLINCKRODT LLC
Approved Prior to Jan 1, 1982
Strength(s): EQ 10MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB], EQ 75MG BASE [RLD][AB]
Has a generic version of Pamelor been approved?
Yes. The following products are equivalent to Pamelor:
nortriptyline hydrochloride capsule; oral
Manufacturer: MYLAN
Approval date: July 26, 1993
Strength(s): EQ 10MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: TARO
Approval date: May 8, 2000
Strength(s): EQ 10MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: TEVA
Approval date: March 27, 1995
Strength(s): EQ 10MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: WATSON LABS
Approval date: March 30, 1992
Strength(s): EQ 10MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB], EQ 75MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pamelor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Pamelor.
See also...
- Pamelor Consumer Information (Wolters Kluwer)
- Pamelor Solution Consumer Information (Wolters Kluwer)
- Pamelor Consumer Information (Cerner Multum)
- Pamelor Advanced Consumer Information (Micromedex)
- Pamelor AHFS DI Monographs (ASHP)
- Nortriptyline Consumer Information (Drugs.com)
- Nortriptyline Consumer Information (Wolters Kluwer)
- Nortriptyline Solution Consumer Information (Wolters Kluwer)
- Nortriptyline Consumer Information (Cerner Multum)
- Nortriptyline Advanced Consumer Information (Micromedex)
- Nortriptyline Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment